Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study to Assess the Safety and Efficacy of Lorvotuzumab Mertansine in Combination With Carboplatin/Etoposide in Patients With Advanced Solid Tumors Including Extensive Stage Small Cell Lung Cancer

NCT01237678 is registered in ClinicalTrials.gov with ImmunoGen, Inc. as lead sponsor.

NCT NCT01237678
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01237678 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study to Assess the Safety and Efficacy of Lorvotuzumab Mertansine in Combination With Carboplatin/Etoposide in Patients With Advanced Solid Tumors Including Extensive Stage Small Cell Lung Cancer
Lead sponsor
ImmunoGen, Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
November 30, 2010
Completion date
May 31, 2015
Enrollment
181 (actual)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung cancer